Medicago
http://www.medicago.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Medicago
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
GSK/Medicago COVID-19 Vaccine Looks Like Also-Ran But Antibody Shows Value Against Omicron
GSK looks unlikely to be a major player in COVID-19 vaccines, even in boosters, but its partnership with Vir could pay off handsomely.
Philip Morris Rebuts 'Cynical' Claims About £1bn Vectura Buy
Buying the UK inhalation specialist Vectura will be key to the transformation of Philip Morris International as it looks to reduce its reliance on smoking products, CEO Jacek Olczak has declared.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
- Other Names / Subsidiaries
-
- Medicago USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice